Neurokinin-1 receptor antagonists: a comprehensive patent survey

被引：47

作者：

Huang, Shih-Chung ^{[2
]}

Korlipara, Vijaya L. ^{[1
]}

机构：

[1] St Johns Univ, Coll Pharm & Allied Hlth Profess, Dept Pharmaceut Sci, Queens, NY 11439 USA

[2] Millennium Takeda Oncol Co, Cambridge, MA 02139 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2010年 / 20卷 / 08期

关键词：

emesis; neurokinin-1; antagonists; receptor; substance P; tachykinin; SUBSTANCE-P ANTAGONISTS; PAINFUL DIABETIC-NEUROPATHY; SELECTIVE NK1 ANTAGONISTS; CISPLATIN-INDUCED EMESIS; GLIOMA-CELL LINES; NK-1; RECEPTOR; ANTITUMORAL ACTION; MITOGENIC ACTION; NK1-RECEPTOR ANTAGONIST; NONPEPTIDE ANTAGONIST;

D O I：

10.1517/13543776.2010.495121

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Importance of the field: Substance P is involved in mediating a number of biological effects such as emesis, pain, inflammation, bronchoconstriction, antitumor activity, and regulation of gastrointestinal and CNS function by binding to the neurokinin-1 (NK1) receptor. Antagonists of this receptor have the potential to be useful in the treatment of various disease conditions. Areas covered in this review: More than 300 patents have been filed by nearly 20 companies and 2 academic institutions in the past 2 decades. This review provides an overview of the patenting activity in the NK1 antagonist field over the last 20 years. What the reader will gain: Chemically diverse non-peptide NK1 receptor antagonists have been identified since the discovery of CP-96,345 by Pfizer in 1991. Representative examples of patented ligands and their biological activities are presented in a company-wise approach. Take home message: The NK1 receptor research has led to the clinical introduction of aprepitant in 2003 and its water soluble injectable form, fosaprepitant dimeglumine, in 2009 by Merck for the prevention of postoperative nausea and vomiting and for inhibiting chemotherapy-induced nausea and vomiting. In addition, maropitant citrate received approval in 2007 for veterinary use.

引用

页码：1019 / 1045

页数：27

共 161 条

[101]

OBACH RS, 1999, Patent No. 9925714

[102] SAR of 2-benzyl-4-aminopiperidines: CGP 49823, an orally and centrally active non-peptide NK1 antagonist [J].

Ofner, S ;

Hauser, K ;

Schilling, W ;

Vassout, A ;

Veenstra, SJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (14) :1623-1628

[103] Naphtho[2,1-b][1,5] and [1,2-f][1,4]oxazocines as selective NK1 antagonists [J].

Ohnmacht, CJ ;

Albert, JS ;

Bernstein, PR ;

Rumsey, WL ;

Masek, BB ;

Dembofsky, BT ;

Koether, GM ;

Andisik, DW ;

Aharony, D .

BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (10) :2653-2669

[104]

Owen S. N., 2000, World Patent, Patent No. [W0000056727, 000056727]

[105] New challenges in the study of the mammalian tachykinins [J].

Page, NM .

PEPTIDES, 2005, 26 (08) :1356-1368

[106]

Paliwal S., 2003, World Patent, Patent No. [03051840, W003051840]

[107] Discovery of a novel, potent and orally active series of γ-lactams as selective NK1 antagonists [J].

Paliwal, Sunil ;

Reichard, Gregory A. ;

Shah, Sapna ;

Wrobleski, Michelle Laci ;

Wang, Cheng ;

Stengone, Carmine ;

Tsui, Hon-Chung ;

Xiao, Dong ;

Duffy, Ruth A. ;

Lachowicz, Jean E. ;

Nomeir, Amin A. ;

Varty, Geoffrey B. ;

Shih, Neng-Yang .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (14) :4168-4171

[108] Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors [J].

Palma, C ;

Nardelli, F ;

Manzini, S ;

Maggi, CA .

BRITISH JOURNAL OF CANCER, 1999, 79 (02) :236-243

[109]

Palma C, 2000, BRIT J CANCER, V82, P480

[110] Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature [J].

Patacchini, R ;

Lecci, A ;

Holzer, P ;

Maggi, CA .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (01) :1-3

← 6 7 8 9 10 11 12 13 14 15 →